| abstract |
Disclosed is diphenyl ether of general formula (I) or a salt thereof, wherein: R1, R2, R7, R8, R9, R10 and A are defined in the specification for treating inflammatory conditions, immune disorders, asthma, allergic rhinitis, eczema, psoriasis, atopic dermatitis, fever, sepsis, systemic lupus erythematosus, diabetes, rheumatoid arthritis, multiple sclerosis, atherosclerosis, transplant rejection, inflammatory bowel disease, cancer, viral infection, thrombosis, fibrosis, flushing, Crohn's disease, ulcerative colitis, chronic obstructive pulmonary disease, inflammation, pain, conjunctivitis, nasal congestion and urticaria. Also disclosed is a process for the preparation of said compound which comprises (a) reacting an aryl cyano ester with a corresponding phenol in the presence of a base; or (b) reducing a corresponding diphenylether; or (c) cleaving a succinimide; or (d) reacting a corresponding amine with a sulfonyl or acid, (e) coupling a diphenylether with an amine or carboxylic acid or (f) coupling and aryl chloride with the corresponding phenol ester or (g) coupling phenyl aldehyde, with a in the presence of a base, followed by converting the carbonyl group to a carboxyl group; or (i) reacting a corresponding diphenylether with a Negishi organozinc compound, in the presence of a palladium (0) catalyst, or with a boronic acid in the presence of a base and a palladium (0) catalyst, or (j) treating a diazonium salt with hydrogen fluoride; and removing any protecting group or groups and, if desired, forming a salt. |